Ardsley Advisory Partners’s AstraZeneca AZN Stock Holding History

Ardsley Advisory Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-50,000	Closed	-$5.48M	–	122
2022 Q3	$5.48M	Sell	50,000 -33,000	-40%	-$4.19M	1.23%	27
2022 Q2	$11M	Sell	83,000 -7,500	-8%	-$984K	1.8%	14
2022 Q1	$12M	Buy	90,500 +90,175	+27,746%	+$10.8M	2%	12
2021 Q4	$38K	Sell	325 -150,025	-100%	-$17.7M	0.01%	105
2021 Q3	$18.1M	Buy	150,350 +75,350	+100%	+$8.77M	2.75%	9
2021 Q2	$8.98M	Buy	+75,000	New	+$8.23M	1.06%	26
2020 Q4	–	Sell	-4,750	Closed	-$521K	–	139
2020 Q3	$521K	Sell	4,750 -2,500	-34%	-$278K	0.1%	95
2020 Q2	$767K	Buy	+7,250	New	+$749K	0.16%	68
2020 Q1	–	Sell	-3,750	Closed	-$374K	–	107
2019 Q4	$374K	Buy	+3,750	New	+$353K	0.06%	111

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Ardsley Advisory Partners's AZN Position: Q4 2022 in Review

Ardsley Advisory Partners sold out of AstraZeneca (AZN) in Q4 2022, closing a stake of 50,000 shares — an estimated $5.48M sold.

Ardsley Advisory Partners first reported a position in AZN in Q4 2019 and held it in 9 quarters. The position peaked at $18.1M in Q3 2021. 1,061 funds tracked by Wall St. Rank hold AZN as of Q4 2022.

Ardsley Advisory Partners reported no remaining AstraZeneca position as of Q4 2022 after selling out during the quarter.
Ardsley Advisory Partners sold 50,000 AstraZeneca shares in Q4 2022, an estimated $5.48M.
Ardsley Advisory Partners first reported a position in AstraZeneca in Q4 2019 and held it in 9 quarters.
Ardsley Advisory Partners's AstraZeneca position peaked at $18.1M in Q3 2021.
1,061 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2022.

Based on Ardsley Advisory Partners's 13F filing for Q4 2022, filed 14 Feb 2023.